Supreme Court To Hear Case That May Reshape Biopharma Research
After months of anticipation, the US Supreme Court today will hear arguments about a case that raises crucial questions about whether human genes can be patented. And the outcome may well reset the boundaries and direction of medical research in the US, which of course has tremendous implications for investments made by the biopharmaceutical industry and the battle against many diseases, notably cancer.
The court will review a lower ruling that upheld the right of Myriad Genetics to patent two human genes that form the basis of a widely used genetic test for breast and ovarian cancers. A decision last year by a federal appeals court gave Myriad the right to patent two so-called isolated human genes – BRCA1 and BRCA2 – that account for most inherited forms of the cancer (here is the appeals court decision and here is the petition to the Supreme Court).
via Supreme Court To Hear Case That May Reshape Biopharma Research | Pharmalive.